Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371743 | 1.00 | KDM4E (0.56) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL3371251 | 1.00 | KDM4E (0.56) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL3800695 | 1.00 | KDM4E (0.56) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL17833168 | 0.98 | KDM4E (0.54) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL17833039 | 0.96 | KDM4E (0.50) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL3680834 | 0.88 | KDM4E (0.52) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL22321686 | 0.88 | KDM4E (0.52) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL3373994 | 0.88 | KDM4E (0.52) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL17833157 | 0.86 | ANPEP (0.41) | KDM4ELMNAL3MBTL1TDP1ANPEP | |
| SCHEMBL4128441 | 0.86 | KDM4E (0.50) | KDM4ELMNAL3MBTL1TDP1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406150-B2 | Method for treatment of primary hormone resistant endometrial and breast cancers | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| EP-3215137-A1 | METHOD FOR TREATMENT OF PRIMARY HORMONE RESISTANT ENDOMETRIAL AND BREAST CANCERS | Lipoxen Technologies Limited (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-20170202827-A1 | Method for Treatment of Primary Hormone Resistant Endometrial and Breast Cancers | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170202854-A1 | Method for Treatment of Primary Hormone Resistant Endometrial and Breast Cancers | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| WO-2016071520-A1 | METHOD FOR TREATMENT OF PRIMARY HORMONE RESISTANT ENDOMETRIAL AND BREAST CANCERS | KEVELT LTD. (EE) | 2016-05-12 | — | — | WO | disclosed |
| US-20100087399-A1 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER | SURKOV KIRILL GENNADIEVICH | 2010-04-08 | — | — | US | disclosed |
| WO-2008121029-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID AND/OR SALTS AND/OR ITS ESTERS THEREOF FOR THE TREATMENT AND PROPHYLAXIS OF MALIGNANT TUMORS OF FEMALE REPRODUCTIVE SYSTEM | SURKOV KIRILL GENNEDIEVICH (RU) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121028-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER | SURKOV KIRILL GENNEDIEVICH (RU) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008024026-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR THE TREATMENT, PROPHYLAXIS OR RELAPSE PREVENTION OF PROSTATE CANCER | SURKOV KIRILL GENNADIEVICH (RU) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024027-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR ENHANCING THE EFFICACY OF ANTIANDROGENIC TREATMENT | SURKOV KIRILL GENNADIEVICH (RU) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087399-A1 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER | ACR, APEH, CA9 | KDM4E 2986/4885LMNA 3366/4885L3MBTL1 3600/4885 |
| US-10406150-B2 | Method for treatment of primary hormone resistant endometrial and breast cancers | PGR, ESR1, ESR2 | KDM4E 1056/4885LMNA 3864/4885L3MBTL1 4805/4885 |
| US-20170202854-A1 | Method for Treatment of Primary Hormone Resistant Endometrial and Breast Cancers | PGR, ESR1, ESR2 | KDM4E 1056/4885LMNA 3864/4885L3MBTL1 4805/4885 |
| US-20170202827-A1 | Method for Treatment of Primary Hormone Resistant Endometrial and Breast Cancers | PGR, ESR1, ESR2 | KDM4E 1056/4885LMNA 3864/4885L3MBTL1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.